Clinical trials: Ovarian Diseases
Ovarian Neoplasm, Fallopian Tube Cancer
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Background: Sorafenib and bevacizumab are anti-cancer drugs that work by targeting the blood vessels that allow tumors to grow. Using the two drugs together may more effectively block the formation of blood vessels that feed…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00436215
- Testing
- Bevacizumab, BAY 43-9006
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Carcinoma, Ovarian Epithelial
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD)…
- Conditions
- Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer
- Trial name
- NCT04196257
- Testing
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bio-Path Holdings, Inc.
No Explained Sterility
Step Up Versus Step Down in Controlled Ovarian Stimulation
The aim of the study is to evaluate if the Step up protocol is equal or superior regarding efficacy and security than the step down protocol. In couple submitted two intrauterine insemination.
- Trial name
- NCT01376999
- Testing
- FSH-r (Follicule stimulate hormone)
- Where
- Spain
- Volunteers
- 158 people
- Sponsor
- Parc de Salut Mar
Epithelial Ovarian Cancer, Circulating Tumor DNA
ctDNA Methylation for Epithelial Ovarian Cancer
Ovarian cancer is one of the most dangerous and predominant gynecological cancers, with a high cancer-related mortality rate in women.
- Conditions
- Epithelial Ovarian Cancer, Circulating Tumor DNA, DNA Methylation, Non-invasive Diagnosis
- Trial name
- NCT05801263
- Testing
- CDO1 and HOXA9 methylation assay
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Lei Li
Benign Ovarian Cyst
Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function
This study aims to evaluate the efficacy of preservation of ovarian function, hemostasis, and safety of a hemostatic agent versus suturing during laparoscopic ovarian cystectomy for ovarian endometriosis.
- Trial name
- PRAHA-2 (NCT04643106)
- Testing
- Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy, suturing with barbed sutures during laparoscopic ovarian cystectomy
- Where
- 2 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Cancer, Ovarian Cancer
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade…
- Trial name
- NCT07371104
- Testing
- DWZ2501 (Olaparib 150mg), DWC202510 (Olaparib 150mg)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Breast Cancer, Ovarian Neoplasm
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
Paclitaxel, a widely used chemotherapeutic agent, is associated with several well-known side effects including neuropathy (weakness, numbness and pain) and generalized body aches.
- Conditions
- Breast Cancer, Ovarian Neoplasm, Pain
- Trial name
- NCT01821833
- Testing
- Omega-3 fatty acid, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- New Mexico Cancer Research Alliance
Ovarian Cancer, Prostate Cancer
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites.
- Trial name
- NCT04560452
- Where
- 37 sites in China
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
Ovarian Cancer
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied
- Trial name
- NCT05410015
- Testing
- Normal clinical treatment without intervention
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer
Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer.
- Trial name
- NCT00170664
- Testing
- Paclitaxel, Carboplatin
- Where
- Germany
- Volunteers
- 129 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00939809
- Testing
- Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis
- Where
- 16 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women
RATIONALE: Screening tests may help doctors detect ovarian cancer early when the survival is much more encouraging. It is not yet known whether a CA125-based or ultrasound strategy is more effective in detecting ovarian cancer…
- Trial name
- UKCTOCS (NCT00058032)
- Testing
- screening questionnaire administration, annual screening
- Volunteers
- 202,638 people, healthy volunteers welcome
- Sponsor
- University College, London
Infertility
Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)
The purpose of this study is to show that a single injection of SCH 900962/MK-8962 is non-inferior to daily injections of recombinant follicle-stimulating hormone (recFSH) during the first week of ovarian stimulation in terms of…
- Trial name
- PURSUE (NCT01144416)
- Testing
- SCH 900962 / Corifollitropin alfa / Org 36286, RecFSH / follitropin beta
- Volunteers
- 1,424 people
- Sponsor
- Organon and Co
Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors
Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.
Granulosa Cell ovarian carcinoma is an infrequent subtype of neoplasia well differentiated from epithelial tumors. They account for 5% of all ovarian malignancies and, with an incidence of 0.4-1.2 cases per 100000 habitants, is…
- Trial name
- Greko II (NCT02101684)
- Testing
- Orteronel 300mg BID
- Where
- 9 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Grupo Español de Tumores Huérfanos e Infrecuentes
Ovarian Carcinoma
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy.
- Trial name
- IFFaLCCO (NCT02297958)
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Rennes University Hospital
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00096200
- Testing
- Carboplatin, Paclitaxel, Sorafenib Tosylate
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Carcinomatosis
Peritoneal Carcinomatosis Extent Evaluation: Radiologic, Laparoscopic and Pathologic.
pathologically proved ovarian cancer patients that underwent contrast enhanced abdomino-pelvic CT and diagnostic laparoscopy before cytoreductive surgery (CRS) will be included in the study.
- Trial name
- NCT03798132
- Testing
- laparoscopy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Shimaa Abdalla Ahmed
Ovarian Cancer
The Effect of TRA-8 on Ovarian Cancer Tissue
The goal of this study is to determine the apoptosis-inducing efficacy of TRA-8 in patient ovarian cancer tissues using a tissue slice technology.
- Trial name
- NCT00711932
- Where
- United States
- Volunteers
- 478 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Cancer Lung, Metastatic Ovarian Cancer
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
This is a clinical trial category C as this is a first in man trial with an unapproved investigational product. Nevertheless the risk is considered low due to the low dose ≤ 10μg.
- Trial name
- NCT03242993
- Testing
- [18F]-AzaFol, folarell
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University of Lausanne Hospitals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.